Lupin Gains FDA Approval for Generic Colonoscopy Prep Drug with 180-Day First-to-File Exclusivity

Lupin's ANDA approval for a generic colonoscopy preparation drug carries a competitive window that most generics manufacturers rarely secure: 180-day first-to-file exclusivity in the U.S. market, positioning the company as the sole generic supplier during that period and setting a near-term revenue floor before the market opens to additional filers.

The approval, granted by the U.S. Food and Drug Administration, confirms Lupin as the exclusive first-to-file applicant under the Hatch-Waxman framework. That designation is not automatic, it requires filing the ANDA first among paragraph IV challengers and successfully defending or settling any resulting patent litigation. For regulatory affairs leads tracking competitive ANDA pipelines, the outcome reflects a disciplined first-to-file strategy executed from the earliest stages of product selection through submission.

From a manufacturing and quality standpoint, colonoscopy preparation formulations present specific process validation considerations. These are typically oral solution or powder-for-solution products with osmotic laxative mechanisms, where 21 CFR Part 211 compliance around dissolution, particulate control, and container-closure integrity is closely scrutinised during pre-approval inspections. Lupin's clearance signals that its manufacturing site met FDA's current GMP expectations for this dosage form at the time of review.

The 180-day exclusivity period is a finite but commercially significant asset. During this window, Lupin can price closer to the reference listed drug without generic competition, recovering development and regulatory costs before the market normalises. For plant heads and supply chain leads, the immediate operational priority is ensuring production capacity and supply continuity are in place before exclusivity launch, any stockout during this window forfeits margin that cannot be recovered once additional ANDAs are approved.

The colonoscopy preparation segment in the U.S. is a defined, recurring-demand category tied to colorectal cancer screening guidelines, giving the approved product a stable demand profile that reduces commercial risk during the exclusivity window.

The 180-day clock begins upon first commercial marketing, making the timing of Lupin's commercial launch the next measurable checkpoint for the company's U.S. generics portfolio.

Source: Media4Growth via Indian Pharma Post, 29 May 2026.